par Andreozzi, Fabio;Massaro, Fulvio;Wittnebel, Sebastian 
;Spilleboudt, Chloé ;Lewalle, Philippe ;Salaroli, Adriano
Référence International journal of molecular sciences, 23, 7, 3887
Publication Publié, 2022-04
;Spilleboudt, Chloé ;Lewalle, Philippe ;Salaroli, AdrianoRéférence International journal of molecular sciences, 23, 7, 3887
Publication Publié, 2022-04
Article révisé par les pairs
| Résumé : | For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2- inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML. |
